Navigation Links
Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
Date:10/21/2011

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at KV Pharmaceutical Company (NYSE: KV-A, KV-B).

(Logo: http://photos.prnewswire.com/prnh/20111014/MM87207LOGO)

Robbins Umeda LLP's investigation focuses on whether officials at KV Pharmaceuticals breached their fiduciary duties to shareholders, maintained woefully inadequate controls, and wasted corporate assets to the detriment of the company and investors.  In particular, the firm is investigating allegations that officials at the company caused KV Pharmaceuticals to misrepresent the extent of expanded patent access granted by the U.S. Food and Drug Administration (the "FDA") for its Makena product line.  After gaining FDA approval, officials at the company made the decision to increase the price of Makena by over 1490% to $1,500.  

On March 17, 2011, two United Stated Senators sent a letter to the Federal Trade Commission stating that "KV Pharmaceuticals actions will result in diminished access to appropriate healthcare for women and result in increased preterm birth." Additionally, on March 30, 2011, the FDA issued a statement that it would not take enforcement action against companies that manufactured compound or generic versions of Makena.

Since these facts have emerged, KV Pharmaceuticals has been forced to lower the price of its Makena product line.  In addition, the company is increasingly the subject of costly public and legal scrutiny.  These events have apparently taken its toll on KV Pharmaceutical's stock price.  After recently trading as high as $13.07 per share on March 8, 2011, shares of KV Pharmaceuticals closed on October 19, 2011, at just $1.39 per share.  

If you own shares of KV Pharmaceuticals and would like more information about your rights, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or via the shareholder information form on our website.  

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/kv-pharmaceuticals/

Attorney Advertising.


'/>"/>
SOURCE Robbins Umeda LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Robbins & Myers Announces Regular Quarterly Cash Dividend
2. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
3. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
4. Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Present at KeyBanc Capital Markets Conference
7. Robbins & Myers to Present at Bairds 2010 Industrial Conference November 9, 2010
8. Robbins Geller Rudman & Dowd LLP Announces Notice of Hearing to Determine Approval of Proposed Settlement of Class Action
9. Robbins & Myers to Release Financial Results for Second Quarter Fiscal 2011
10. Robbins & Myers Completes Sale of Romaco Businesses
11. Robbins & Myers Announces Regular Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... , ... Providing for loved ones before one’s passing is of paramount importance. ... begin. “Now more than ever there are some questions that are far too critical ... said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... to experienced, personalized dental care since 1985. After thirty-two years, Dr. Latner has become ... privilege to help my numerous clients over the years with all their dental needs,” ...
(Date:4/21/2017)... Miami, Fl (PRWEB) , ... April 21, 2017 , ... ... Earth Day is a day to clean, plant trees and look forward to a ... green isn’t just about doing something outdoors. Indoor air quality can be two to ...
(Date:4/21/2017)... ... April 21, 2017 , ... Federal ... five common elements between the Obamacare program that most Republicans love to hate ... Warfarin poison to kill hogs. , Like Obamacare, the Miller program centers ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... a significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering ... of IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet ...
Breaking Medicine News(10 mins):